BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 29934663)

  • 1. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP Apparatus 2 and 3.
    Cacace J; Reilly EE; Amann A
    AAPS PharmSciTech; 2004 Feb; 5(1):E6. PubMed ID: 15198527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
    Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
    J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
    Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
    Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State.
    Zhang G; Sun M; Jiang S; Wang L; Tan Y; Wang L; Cheng Z
    J Pharm Sci; 2021 Mar; 110(3):1240-1247. PubMed ID: 33096138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
    Gonçalves de Lima L; Rossi de Campos D
    Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
    Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
    J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
    Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
    AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine.
    García MA; Cristofoletti R; Abrahamsson B; Groot DW; Parr A; Polli JE; Mehta M; Shah VP; Tomakazu T; Dressman JB; Langguth P
    J Pharm Sci; 2021 May; 110(5):1935-1947. PubMed ID: 33610571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration.
    Li ZQ; Tian S; Gu H; Wu ZG; Nyagblordzro M; Feng G; He X
    AAPS PharmSciTech; 2018 May; 19(4):1882-1893. PubMed ID: 29663288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of
    Zhang S; Fang M; Zhang Q; Li X; Zhang T
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1646-1653. PubMed ID: 31342807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of USP Apparatus 3 Dissolution Method with IVIVC for Extended Release Tablets of Metformin Hydrochloride and Development of a Generic Formulation.
    Mendes TC; Simon A; Menezes JCV; Pinto EC; Cabral LM; de Sousa VP
    Chem Pharm Bull (Tokyo); 2019; 67(1):23-31. PubMed ID: 30606948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.